Home › Acute Myeloid Leukemia › New Jersey › Clifton
Acute Myeloid Leukemia clinical trials in Clifton, NJ
12 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Clifton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RecruitingPhase 1
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · 7 mi away
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · 7 mi away
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Hackensack University Medical Center, Hackensack · 7 mi away
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RecruitingPhase 2
- John Theurer Cancer Center at Hackensack UMC, Hackensack · 7 mi away
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Hackensack University Medical Center, Hackensack · 7 mi away
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RecruitingPhase 3
- Hackensack University Medical Center, HMH, Hackensack · 7 mi away
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · 7 mi away
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · 7 mi away
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Hackensack University Medical Center, Hackensack · 7 mi away
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- John Theurer Cancer Center / Hackensack University, Hackensack · 7 mi away
Phase IB/II of CPX-351 for Relapse Prevention in AML
RecruitingPhase 1/2
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack · 7 mi away
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- Hackensack University Medical Center, Hackensack · 7 mi away
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX85 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Seattle, WA41 studies
- Baldwin Park, CA40 studies
- Columbus, OH35 studies
- Philadelphia, PA34 studies
- Durham, NC33 studies
- Atlanta, GA31 studies
- Tampa, FL29 studies
- Chicago, IL26 studies
- Portland, OR25 studies
Other studies in Clifton
- Non-Small Cell Lung Cancer24 studies
- Cancer (all types)15 studies
- Multiple Myeloma14 studies
- Metastatic Cancer12 studies
- Breast Cancer12 studies
- Prostate Cancer12 studies
- Ovarian Cancer11 studies
- Lung Cancer10 studies
- Colorectal Cancer8 studies
- Head and Neck Squamous Cell Carcinoma8 studies
- Endometrial Cancer8 studies
- Heart Failure8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.